Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Nov 1;31(11):6803-6813.
doi: 10.3390/curroncol31110502.

Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study

Sercan Ön  1 , Barış Köksal  2 , Zafer Arık  2 , Burcu Caner  3 , Duygu Ercan Uzundal  4 , Ozan Yazıcı  4 , Burcu Arslan Benli  5 , Eda Eylemer Mocan  6 , Can Güngör  7 , Zeynep Gülsüm Güç  8 , Seval Akay  9 , Merve Keskinkılıç  10 , Hande Dik Avcı  11 , Burçak Karaca Yayla  12 , Burcu Çakar  12 , Ulus Ali Şanlı  12
Affiliations
Multicenter Study

Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study

Sercan Ön et al. Curr Oncol. .

Abstract

(1) Background: Metastatic L-type sarcomas (liposarcoma and leiomyosarcoma) are rare and have a poor prognosis. Trabectedin is an effective agent that can be used after anthracyclines. This study was designed to evaluate the real-life effectiveness and safety of trabectedin. (2) Methods: A retrospective multicenter study was conducted on patients who were treated with trabectedin for metastatic L-type sarcomas at ten tertiary oncology centers between 2015 and 2023. The objective response rate (ORR), disease control rate (DCR), time to treatment failure (TTF), and overall survival (OS) were evaluated in the cohort. Cox regression analysis was used to determine prognostic factors for survival. (3) Results: A total of 98 patients (52% liposarcoma and 48% leiomyosarcoma) were included in the study. The median treatment line was three (range: 1 to 6). Thirteen patients (13.3%) underwent local treatment due to oligoprogression, and dose reduction was required in seventeen patients (17.3%) due to toxicity. The ORR and DCR were 16% and 42%, respectively. The median TTF was 3 months, and the median OS was 10 months. In univariate analysis, a significantly longer median TTF was observed in patients who underwent local treatment (p = 0.008), obtained objective responses (p < 0.001), and underwent dose reduction (p = 0.002). No statistical differences were observed according to the histologic subtype and metastatic site. In the multivariate analysis for OS, it was found that obtaining an objective response was a good prognostic factor (p = 0.003), while the presence of liver metastases was associated with a poor prognosis (p = 0.016). (4) Conclusion: Trabectedin is a suitable option for L-type sarcoma after doxorubicin-based treatments. Survival was not worse in patients who underwent dose reduction. The use of local therapies simultaneously with trabectedin can be effective.

Keywords: drug toxicity; ecteinascidin 743; leiomyosarcomas; liposarcomas; targeted radiation therapy; trabectedin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curve for time to treatment failure in the overall study population.
Figure 2
Figure 2
Kaplan–Meier curve for time to treatment failure according to histologic subtype.
Figure 3
Figure 3
Kaplan–Meier curve for overall survival in the overall study population.
Figure 4
Figure 4
Kaplan–Meier curve for overall survival according to histologic subtype.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 2023;73:17–48. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Choi J.H., Ro J.Y. The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv. Anat. Pathol. 2021;28:44–58. doi: 10.1097/PAP.0000000000000284. - DOI - PubMed
    1. Ducimetière F., Lurkin A., Ranchère-Vince D., Decouvelaere A.-V., Péoc’H M., Istier L., Chalabreysse P., Muller C., Alberti L., Bringuier P.-P., et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS ONE. 2011;6:e20294. doi: 10.1371/journal.pone.0020294. - DOI - PMC - PubMed
    1. Conyers R., Young S., Thomas D.M. Liposarcoma: Molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. doi: 10.1155/2011/483154. - DOI - PMC - PubMed
    1. Rao U.N., Finkelstein S.D., Jones M.W. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod. Pathol. 1999;12:1001–1009. - PubMed

Publication types

Substances

LinkOut - more resources